Betty and Guy Beatty Center for Integrated Research, Inova Health System, Inova Fairfax Hospital, Claude Moore Health Education and Research Building, 3rd Floor, 3300 Gallows Road, Falls Church, VA 22042, USA.
Betty and Guy Beatty Center for Integrated Research, Inova Health System, Inova Fairfax Hospital, Claude Moore Health Education and Research Building, 3rd Floor, 3300 Gallows Road, Falls Church, VA 22042, USA; Department of Medicine, Center for Liver Disease, Inova Fairfax Hospital, Claude Moore Health Education and Research Building, 3rd Floor, 3300 Gallows Road, Falls Church, VA 22042, USA.
Clin Liver Dis. 2017 Nov;21(4):739-753. doi: 10.1016/j.cld.2017.06.010. Epub 2017 Jul 29.
Nonalcoholic fatty liver disease (NAFLD) is recognized as a global health problem and as a common cause of chronic liver disease. Nonalcoholic steatohepatitis (NASH) carries an increased risk for development of advanced liver disease. Lifestyle modifications with diet and exercise have been the initial management recommendation. However, these changes are difficult to achieve and sustain overtime. There are pharmacologic agents being considered for treatment of NASH. Some target insulin resistance and others focus on oxidative stress, inflammation, apoptosis, and fibrosis. There is a great deal of efforts to develop therapeutic regimens for patients with NASH and NASH with significant fibrosis.
非酒精性脂肪性肝病(NAFLD)被认为是一个全球性的健康问题,也是慢性肝病的常见病因。非酒精性脂肪性肝炎(NASH)发生进展性肝病的风险增加。生活方式的改变,包括饮食和运动,一直是最初的管理建议。然而,这些改变很难实现,并且难以长期维持。有一些药物被认为可以治疗 NASH。一些药物针对胰岛素抵抗,另一些则针对氧化应激、炎症、细胞凋亡和纤维化。人们正在努力为 NASH 患者和伴有显著肝纤维化的 NASH 患者开发治疗方案。